Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring

Clinical Chemistry

Volumn 46, Issue 12, 2000, Pages 2050-2068

  Dufour, D R ^a   Lott, J A ^a   Nolte, F S ^a   Gretch, D R ^a   Koff, R S ^a   Seeff, L B ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE HEPATITIS; ALCOHOL LIVER DISEASE; CHRONIC HEPATITIS; DISEASE SEVERITY; HEPATITIS B; HEPATITIS C; HUMAN; LABORATORY DIAGNOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER INJURY; MEDICAL LITERATURE; MEDICAL RESEARCH; PATIENT MONITORING; PRACTICE GUIDELINE; REVIEW; SCREENING;

HEPATITIS C VIRUS;

EID: 0033638414     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/46.12.2050     Document Type: Review

References (220)

1. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests
2. Serum enzyme tests in diseases of the liver and biliary tree
3. Computer analysis of liver function tests and their interrelationship in 347 cases of viral hepatitis
4. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin
5. Prospective study of clinical and biochemical features of symptomatic choledocholithiasis
6. Marked elevation of serum transaminase activity associated with extrahepatic biliary tract disease
7. Graphical analysis of laboratory data in the differential diagnosis of cholestasis: A computer-assisted prospective study
8. Alcoholic hepatitis
9. Alcoholic hepatitis - A clinical and pathological study of 142 cases
10. VA Cooperative Study on Alcoholic Hepatitis. IV. The significance of clinically mild alcoholic hepatitis - Describing the population with minimal hyperbilirubinemia
11. Prognostic significance of cholestatic alcoholic hepatitis
12. The SGOT/SGPT ratio - An indicator of alcoholic liver disease
13. A three-year survey of viral hepatitis in West London
14. Frequency of illness associated with epidemic hepatitis A virus infections in adults
15. Hepatitis B: Diagnosis, prevention, and treatment
16. Acute hepatitis B virus infection: Relation of age to the clinical expression of disease and subsequent development of the carrier state
17. Hepatitis C: The clinical spectrum of disease
18. VA Cooperative Study of Post-Transfusion Hepatitis, 1969-1974: Incidence and characteristics of hepatitis and responsible risk factors
19. Ischemic hepatitis: Widening horizons
20. Assessment of prognosis in fulminant hepatic failure
21. Coagulation studies as a prognostic index in acute liver failure
22. Kinetics of (14C) cholic acid in fulminant hepatic failure: A prognostic test
23. Early indicators of prognosis in fulminant hepatic failure
24. Prothrombin time in fulminant hepatic failure
25. Assessment of the validity of the INR system for patients with liver impairment
26. Laboratory identification of ischemic hepatitis (shock liver)
27. The temporal profile of increased transaminase levels in patients with acetaminophen-induced liver dysfunction
28. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure
29. Prevention, diagnosis, and management of viral hepatitis: A guide for primary care physicians
30. Specific immunoglobulin M response to hepatitis A virus determined by solid phase radioimmunoassay
31. Hepatitis A in Greenland: Importance of specific antibody testing in epidemiologic surveillance
32. Seroepidemiology of hepatitis A in the United States
33. IgM antibody to hepatitis B core antigen as a diagnostic parameter of acute infection with hepatitis B virus
34. A serologic follow-up of the 1942 epidemic of post-vaccination hepatitis in the United States Army
35. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications
36. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection
37. The natural history of community acquired hepatitis C in the United States
38. The epidemiology of hepatitis viruses B, C, and D
39. Hepatotoxicity of analgesics and anti-inflammatory agents
40. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: Analysis of instances of therapeutic misadventure
41. Ischemic hepatitis: Clinical and laboratory observations of 34 patients
42. Extreme serum elevations of aspartate aminotransferase
43. Hepatic dysfunction accompanying acute cocaine intoxication
44. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis
45. Relation of disease activity during chronic hepatitis C infection to complexity of hypervariable region 1 quasispecies
46. The transaminase tests in liver disease
47. Clinical manifestations of hepatitis A. Recent experience in a community teaching hospital
48. Hepatitis A virus in stool during clinical relapse
49. Relapsing hepatitis A: Review of 14 cases and literature survey
50. A prospective community-based evaluation of liver enzymes in individuals with hepatitis C after drug use
51. Reactivation of chronic type B hepatitis presenting as acute viral hepatitis
52. The natural history of asymptomatic hepatitis B surface antigen carriers
53. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia
54. Serum bilirubins in hepatobiliary disease: Comparison with other liver function tests and changes in the postobstructive period
55. Prolonged intrahepatic cholestasis secondary to acute hepatitis A
56. Early indicators of prognosis in fulminant hepatic failure
57. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?
58. Hepatitis C in asymptomatic blood donors
59. Slow progression rate of fibrosis in hepatitis C patients with persistently normal alanine aminotransferase activity
60. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
61. Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
62. Detection of chronic liver disease: Costs and benefits
63. Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C infection
64. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis
65. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection
66. Progressive liver functional impairment is associated with an increase in AST/ALT ratio
67. Blood donors with elevated alanine aminotransferase levels - Persistence of elevation and liver histology
68. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases
69. Evaluation of blood donors with elevated serum alanine aminotransferase levels
70. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients
71. Serum alanine aminotransferase (ALT) elevation in asymptomatic US Air Force basic trainee blood donors
72. Effects of habitual exercise on routine laboratory tests
73. Alanine aminotransferase (ALT) levels over time in anti-HCV-positive persons who are HCV RNA positive compared with persons who are HCV RNA negative but RIBA positive
74. Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin
75. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients
76. Nonalcoholic steatohepatitis
77. Nonalcoholic steatohepatitis: An expanded clinical entity
78. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease
79. Nonalcoholic steatohepatitis: Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients
80. Effect of weight reduction on hepatic abnormalities in overweight patients
81. Prevalence of heterozygotes for hemochromatosis in the white population of the United States
82. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis
83. Expression of HLA-linked hemochromatosis in subjects homozygous or heterozygous for the C282Y mutation
84. Distinction between homozygous and heterozygous subjects with hereditary haemochromatosis using iron status markers and receiver operating characteristic (ROC) analysis
85. Mild liver enzyme abnormalities: Eliminating hemochromatosis as cause
86. A population-based study of the clinical expression of the hemochromatosis gene
87. Population screening for hemochrematosis: A comparison of unbound iron binding capacity, transferrin saturation, and C282Y genotyping in 5,211 blood donors
88. Molecular medicine and hemochromatosis: At the crossroads
89. Hereditary hemochromatosis: Gene discovery and its implications for population-based screening
90. Iron overload, public health, and genetics: Evaluating the evidence for hemochromatosis screening
91. Practice guideline development task force of the College of American Pathologists, Hereditary hemochromatosis
92. Screening blood donors for hereditary hemochromatosis: Decision analysis model based on a 30-year database
93. The Wilson disease gene is a putative copper transporting P-type ATP-ase similar to the Menkes gene
94. Wilson disease: Genetic basis of copper toxicity and natural history
95. A study of the caerulcplasmic concentrations found in 75 patients with Wilson's disease their kindreds, and various control groups
96. Hereditary disorders of copper metabolism
97. Muddying the water: Wilson's disease challenges will not soon disappear
98. Antibodies to soluble liver antigen, P450115, and mitochondrial complexes in chronic hepatitis
99. Autoimmune hepatitis: Evolving concepts and treatment strategies
100. Meeting report: International Autoimmune Hepatitis Group
101. Hepatitis C virus infection as a determinant of behavior in type I autoimmune hepatitis
102. Duration and specificity of antibodies to hepatitis C virus in chronic active hepatitis
103. Primary biliary cirrhosis
104. Primary biliary cirrhosis: Identification of two major M2 mitochondrial autoantigens
105. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: Clinical features and response to therapy
106. Frequency and nature of the variant syndromes of autoimmune liver disease
107. Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatitis form of PBC in genetically susceptible individuals
108. Primary sclerosing cholangitis: A clinical review
109. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases
110. Serum autoantibodies, ulcerative colitis, and primary sclerosing cholangitis
111. Antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: Defined specificities may be associated with distinct clinical features
112. 1-antitrypsin
113. 1-Antitrypsin deficiency and liver disease
114. 1-antitrypsin deficient children
115. 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody
116. 1-antitrypsin deficiency
117. 1-Antitrypsin deficiency in liver disease: The extent of the problem
118. 1-antitrypsin deficiency and cirrhosis in adults, a fortuitous association
119. 1-antitrypsin deficiency and chronic liver disease
120. 1-antitrypsin deficiency in adults with chronic active hepatitis and cryptogenic cirrhosis
121. Molecular clone in disease association of hepatitis G virus: A transfusion transmissible agent
122. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease
123. The clinical significance of simultaneous infection with hepatitis G virus in patients with chronic hepatitis C
124. Hepatitis G infection: Role in cryptogenic liver disease and primary liver cancer in the UK
125. Lack of evidence for hepatitis G virus replication in the livers of patients coinfected with hepatitis C and G viruses
126. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology
127. TT-Virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis
128. Transfusion-associated TT virus infection and its relationship to liver disease
129. The role of TT virus infection in acute hepatitis
130. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis
131. Spontaneous loss of HBeAg and development of anti-HBe during long-term follow-up of blood donors found to be HBsAg positive
132. Clinical and histological outcome after hepatitis B e antigen to antibody seroconversion in children with chronic hepatitis B
133. Predictive value of aminotransferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B
134. A one-year trial of lamivudine for chronic hepatitis B
135. Quantitative assessment of serum hepatitis B e antigen, IgM hepatits B core antibody and HBV DNA in monitoring the response to treatment in patients with chronic hepatitis B
136. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B
137. Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B
138. A preliminary trial of lamivudine for chronic hepatitis B infection
139. Hepatitis B surface gene mutants and their emerging role in the efficacy of HBV vaccination programs
140. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg
141. Incidence and clinical significance of e antigen and antibody in active and chronic liver disease
142. Treatment of chronic hepatitis B infection
143. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection
144. Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification
145. Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: Branched DNA and Amplicor Monitor
146. Natural fluctuations of hepatitis C viral load in a homogeneous patient population: A prospective study
147. Hepatitis C RNA virus profiles in chronically infected individuals: Do they relate to disease activity?
148. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase levels
149. Interferon α-2b or in combination with ribavirin as initial treatment for chronic hepatitis C
150. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
151. Is an 'A la Carte' combination interferon α-2b plus ribavirin regimen possible for first line treatment in patients with chronic hepatitis C?
152. Chronic hepatitis C and interferon α: Conventional and cumulative meta-analyses of randomized clinical trials
153. EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus statement
154. Reuben A Relationship of aminotransferases to liver histological status in chronic hepatitis C
155. Liver histology in hepatitis C infection: A comparison between patients with persistently normal or abnormal transaminases
156. Evaluation of liver histology, ALT elevation, and HCV RNA titer in patients with chronic hepatitis C
157. The role of liver biopsy in hepatitis C
158. Natural history of liver fibrosis progression in patients with chronic hepatitis C
159. Noninvasive diagnosis of hepatic fibrosis or cirrhosis
160. Efficacy of serum laminin measurement for diagnosis of fibrotic liver diseases
161. Serum markers for hepatic fibrosis in alcoholic liver disease: Which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase, or prolyl hydroxylase?
162. Clinical significance of serum 7S collagen in various liver diseases
163. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis
164. Serum laminin and hyaluronan in liver cirrhosis: Markers with high prognostic value
165. A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis
166. Serum angiotensin converting enzyme and C4 protein of complement as a combined diagnostic index in alcoholic liver disease
167. Circulating standard CDP9D isoform in patients with liver disease: Relationship with other soluble adhesion molecules and evaluation of diagnostic usefulness
168. Clinical use of serum markers of fibrosis in chronic hepatitis
169. Progress in the enzyme diagnosis of liver disease: Reality or illusion
170. Serum α-fetoprotein levels in patients with chronic hepatitis C - Relationship with serum alanine amino-transferase values, histologic activity index, and hepatocytes MIB-1 scores
171. Serum α-fetoprotein levels and liver histology in patients with chronic hepatitis C
172. The epidemiology of primary liver cancer
173. Rising incidence of hepatocellular carcinoma in the United States
174. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B
175. Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients
176. Silent cirrhosis in patients with hepatocellular carcinoma. Implications for screening in high-incidence and low-incidence areas
177. Outcome of 67 patients with hepatocellular carcinoma detected during screening or 1125 patients with chronic hepatitis
178. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: Results of a national survey
179. Screening and surveillance of chronic viral hepatitis patients for hepatocellular carcinoma: A seven year study using serum α-fetoprotein and abdominal ultrasound
180. Elevations in serum α-fetoprotein in patients with chronic hepatitis B
181. Workshop on screening for hepatocellular carcinoma
182. Preneoplastic conditions of the liver
183. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis
184. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: Incidence and prevalence of hepatocellular carcinoma in a North American population
185. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal
186. Hepatocellular carcinoma in Italian patients with cirrhosis
187. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
188. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: An 8 years prospective study by ultrasound and α fetoprotein
189. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma
190. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis
191. Screening for hepatocellular carcinoma
192. Growth rate of asymptomatic hepatocellular carcinoma and its clinical significance
193. Asymptomatic hepatocellular carcinoma in Child's A cirrhosis
194. Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival
195. Plasma abnormal prothrombin (des-γ-carboxy prothrombin) as a marker of hepatocellular carcinoma
196. Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma
197. Clinical significance of simultaneous determinations of α-fetoprotein and des-γ-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma
198. Early detection of hepatocellular carcinoma associated with cirrhosis by com bined assay of des-γ-carboxy prothrombin and α-fetoprotein: A prospective study
199. The usefulness of determining des-γ-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma
200. Specificity of increased des-γ-carboxyprothrombin in hepatocellular carcinoma after vitamin K1 injection
201. The effects of vitamin K on the generation of des-γ-carboxy prothrombin in patients with hepatocellular carcinoma
202. Serum des-γ-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma
203. A clinical study of lectin-reactive α-fetoprotein as an early indicator of hepatocellular carcinoma in the follow-up of cirrhotic patients
204. Diagnosis of primary liver cancer using lectin affinity chromatography of serum alkaline phosphatase
205. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specified bands of serum γ-glutamyltransferase
206. Wilson's disease in patients presenting with liver disease: A diagnostic challenge
207. Clinical differentiation of fulminant Wilsonian hepatitis from other Causes of hepatic failure
208. The Wilson disease gene: Spectrum of mutations and their consequences
209. 'Acute' autoimmune hepatitis
210. Prognostic and therapeutic implications of extreme aminotransferase elevation in chronic hepatitis
211. Diagnosis and therapy of autoimmune liver disease
212. Evaluation of assays for antibody to hepatitis E virus by a serum panel
213. Seroreactivity to hepatitis E virus in areas where the disease is not endemic
214. Viremia, fecal shedding, and IgM and IgG responses in patients with hepatitis E
215. Detection of HEV RNA in faeces, by RT-PCR during the epidemics of hepatitis E in India (1976-1995)
216. Hepatic function in mononucleosis induced by Epstein-Barr virus and cytomegalovirus